106 7426-44-1

应用筛选条件

关键词:'106 7426-44-1'

显示 31-34 共 34 条结果关于 "106 7426-44-1" 范围论文

Combination of umbilical cord mesenchymal stem cells and standard immunosuppressive regimen for pediatric patients with severe aplastic anemia.

Yang Lan et al.

BMC pediatrics, 21(1), 102-102 (2021-03-01)

Defects of bone marrow mesenchymal stem cells (BM-MSCs) in proliferation and differentiation are involved in the pathophysiology of aplastic anemia (AA). Infusion of umbilical cord mesenchymal stem cells (UC-MSCs) may improve the efficacy of immunosuppressive therapy (IST) in childhood severe

Gaping lids, gp, a mutation on centromeric chromosome 11 that causes defective eyelid development in mice.

D M Juriloff et al.

Mammalian genome : official journal of the International Mammalian Genome Society, 11(6), 440-447 (2000-05-20)

In mammals, during fetal development, the eyelids grow and flatten over the eyes and temporarily fuse closed. Failure of this normal developmental process in mice leads to the defect, open-eyelids-at-birth. Nearly all newborns of the GP/Bc strain, homozygous for the

[KRAS and BRAF gene mutations in correlation with clinicopathologic features of colorectal carcinoma in Chinese].

Xiao-li Zhu et al.

Zhonghua bing li xue za zhi = Chinese journal of pathology, 41(9), 584-589 (2012-11-20)

To retrospectively analyze KRAS and BRAF gene mutation features in Chinese colorectal cancer (CRC) and their clinicopathologic relationship. 557 colorectal cancer cases were collected, including 325 colon cancer and 232 rectal cancer. PCR amplification and DNA sequencing were used to

Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial.

Niels Wcj van de Donk et al.

The Lancet. Haematology, 5(10), e479-e492 (2018-10-07)

In patients with recently diagnosed multiple myeloma, the HOVON-50 phase 3 trial showed improved event-free survival for thalidomide-containing induction and maintenance regimens (in conjunction with high-dose melphalan and autologous stem cell transplantation [auto-SCT]) after a median of 52 months of

2/2